IP Library Granted Patent US 8,119,602
Granted Patent B2
US 8,119,602 · App. 11/443,793 · Granted Feb 21, 2012

Administration of HCV protease inhibitors in combination with food to improve bioavailability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,119,602
App. No.
11/443,793
Granted
Feb 21, 2012
Kind
B2
Abstract

Methods of treating, preventing or ameliorating one or more symptoms of hepatitis C in a subject comprising the step of administering at least one HCV protease inhibitor in combination with food are provided. Also provided are methods of increasing bioavailability of an HCV protease inhibitor and methods of increasing serum levels of an HCV protease inhibitor in a subject. All methods comprise adminstering at least one HCV protease inhibitor in combination with food, the at least one HCV protease inhibitor selected from the group consisting of compounds of Formulae I-XXVI, described herein. Administration of compounds of the present invention in combination with food provides improved bioavailability and increased peak serum levels of the compounds as compared to administration without food.

Claims (12)

1. A method of increasing the bioavailability of a compound in a subject in need thereof, comprising administering to the subject an effective amount of at least one of the following compounds

or a pharmaceutically acceptable salt thereof, in combination with food comprising high or low fat food, wherein said compound is administered concurrently with, up to ninety minutes after or up to 30 minutes before administration of said food and, wherein the bioavailability achieved is higher compared to that when the compound is administered without food.

2. The method of claim 1 , wherein the total amount of the at least one compound administered over twenty-four hours is between 50 mg and 3,000 mg.

3. The method of claim 2 , wherein the one or more discrete dosages are in oral dosage form.

4. The method of claim 1 wherein the at least one compound is administered in oral dosage form and is administered concurrently with consumption of food.

5. The method of claim 1 wherein the at least one compound is administered in oral dosage form and is administered up to thirty minutes before or up to thirty minutes after consumption of food.

6. The method of claim 1 wherein over 30% of the calories in the food are from fat.

7. The method of claim 1 wherein the at least one compound is administered in combination with at least one antiviral agent which is different from the at least one compound and/or an immunomodulatory agent.

8. A method of increasing bioavailability of the compound in a subject in need thereof of Formula Ia

or a salt thereof, comprising administering to the subject an effective amount of said compound in combination with food, said food comprising high or low fat food.

9. A method of increasing bioavailability of the compound in a subject in need thereof of the structural formula

or a salt thereof, comprising administering to the subject an effective amount of said compound in combination with food, said food comprising high or low fat food.

Assignments (3)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2006
From: GUPTA, SAMIR K.
To: SCHERING CORPORATION
Reel/Frame 018056/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2006
From: ZHANG, JENNY
To: SCHERING CORPORATION
Reel/Frame 018056/0215 →